AnaptysBio
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 117
- Market Cap
- $1.1B
- Website
- http://www.anaptysbio.com
- Introduction
AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
AnaptysBio, Inc. announced CEO Daniel Faga will present at the 43rd Annual J.P. Morgan Healthcare Conference on Jan. 14, 2025. The event will be webcast live and available for replay. AnaptysBio focuses on immunology therapeutics, with key programs including rosnilimab for autoimmune diseases and antibodies in development for immuno-oncology.
Jemperli (dostarlimab-gxly) receives US FDA Breakthrough Therapy Designation
GSK's Jemperli (dostarlimab-gxly) received FDA Breakthrough Therapy Designation for treating dMMR/MSI-H rectal cancer, showing a 100% clinical complete response in 42 patients. This designation aims to expedite development for serious conditions with potential improvement over current therapies, addressing significant quality-of-life impacts of standard care.
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
ANB032, a BTLA agonist, failed to meet primary and secondary endpoints in the ARISE-AD trial for atopic dermatitis, leading to discontinued investment. AnaptysBio will focus on its autoimmune portfolio, including rosnilimab, with Phase 2b data for rheumatoid arthritis expected in February 2025. The company has a cash runway through 2027.
ANAPTYSBIO, INC SEC 10-Q Report
AnaptysBio's Q3 2024 10-Q report shows collaboration revenue up to $30.0M, with a net loss of $(32.9)M. The company advances its pipeline, including rosnilimab in Phase 2b for RA and UC, and ANB032 in Phase 2b for AD. Challenges include product development risks and regulatory approval hurdles.
© Copyright 2025. All Rights Reserved by MedPath